Prenatal Care

Prenatal Care US Medical PG Question 1: A 26-year-old Caucasian G1 presents at 35 weeks gestation with mild vaginal bleeding. She reports no abdominal pain or uterine contractions. She received no prenatal care after 20 weeks gestation because she was traveling. Prior to the current pregnancy, she used oral contraception. At 22 years of age she underwent a cervical polypectomy. She has a 5 pack-year smoking history. The blood pressure is 115/70 mmHg, the heart rate is 88/min, the respiratory rate is 14/min, and the temperature is 36.7℃ (98℉). Abdominal palpation reveals no uterine tenderness or contractions. The fundus is palpable between the umbilicus and the xiphoid process. An ultrasound exam shows placental extension over the internal cervical os. Which of the following factors present in this patient is the risk factor for her condition?

• A. White race
• B. Smoking (Correct Answer)
• C. History of cervical polyp
• D. Intake of oral contraceptives
• E. Nulliparity

Prenatal Care Explanation: **Smoking** - **Smoking** is a well-established risk factor for **placenta previa**, as it impairs placental development and increases the likelihood of abnormal implantation. - Nicotine and other toxins in cigarette smoke can cause **vasoconstriction** and **ischemia**, leading to placental abnormalities, including a lower implantation site. *White race* - While certain ethnicities may have varying rates of obstetrical complications, **white race** is generally not considered an independent or significant risk factor for placenta previa. - Risk factors for placenta previa are primarily related to uterine health, placental development, and obstetric history. *History of cervical polyp* - A history of **cervical polyps** is not a known or significant risk factor for **placenta previa**. - Cervical polyps are benign growths of the cervix and do not inherently affect the site of placental implantation. *Intake of oral contraceptives* - The use of **oral contraceptives** prior to pregnancy is not a risk factor for **placenta previa**. - Oral contraceptives primarily affect ovarian function and have no direct impact on the subsequent placental implantation site. *Nulliparity* - **Nulliparity** (never having given birth) is actually associated with a *lower* risk of placenta previa compared to multiparity. - The risk of placenta previa generally **increases with the number of previous pregnancies** and deliveries due to changes in the uterine lining.

Prenatal Care US Medical PG Question 2: A 30-year-old woman, gravida 2, para 1, comes to the physician because she had a positive pregnancy test at home. During the last two weeks, she has had nausea and two episodes of non-bloody vomiting. She also reports increased urinary frequency. Her pregnancy and delivery of her first child were uncomplicated. Last year, she had two episodes of grand-mal seizure. She is sexually active with her husband and they use condoms inconsistently. She does not smoke or drink alcohol. She does not use illicit drugs. Current medications include valproic acid and a multivitamin. Her vital signs are within normal limits. Physical examination shows no abnormalities. A urine pregnancy test is positive. The child is at increased risk for requiring which of the following interventions?

• A. Lower spinal surgery (Correct Answer)
• B. Cochlear implantation
• C. Kidney transplantation
• D. Dental treatment
• E. Respiratory support

Prenatal Care Explanation: ***Lower spinal surgery*** - The patient is taking **valproic acid** which is associated with an increased risk of **neural tube defects** (NTDs), such as spina bifida, in the fetus. - Infants with **spina bifida** often require surgical intervention to close the spinal defect and manage associated neurological complications such as hydrocephalus, which may consequently require a shunt. *Cochlear implantation* - **Cochlear implantation** is a treatment for severe hearing loss, and there is no direct link between maternal valproic acid use and an increased risk of congenital hearing impairment requiring this intervention. - While some congenital syndromes can include hearing loss, it is not a hallmark teratogenic effect of **valproic acid**. *Kidney transplantation* - There is no strong evidence to suggest that maternal use of **valproic acid** significantly increases the risk of fetal renal malformations or end-stage renal disease requiring **kidney transplantation**. - Issues requiring kidney transplantation are not a common outcome of valproic acid exposure. *Dental treatment* - Routine **dental treatment** is common in children, but there is no specific increased risk of severe dental anomalies or conditions requiring extensive early intervention directly attributable to maternal valproic acid use. - While some medications can cause dental issues, **valproic acid** is not specifically noted for this teratogenic effect. *Respiratory support* - Although some birth defects can indirectly affect respiratory function, there is no direct and significant link between maternal **valproic acid** use and primary pulmonary hypoplasia or other severe respiratory conditions requiring **long-term respiratory support** in the newborn. - **Neural tube defects** are the primary concern, and while they can have systemic effects, primary respiratory failure is not a direct result.

Prenatal Care US Medical PG Question 3: A 21-year-old gravida 1, para 0 woman presents to the family medicine clinic for her first prenatal appointment. She states that she has been taking folic acid supplements daily as directed by her mother. She smokes a few cigarettes a day and has done so for the last 5 years. Pediatric records indicate the patient is measles, mumps, and rubella non-immune. Her heart rate is 78/min, respiratory rate is 14/min, temperature is 36.5°C (97.7°F), and blood pressure is 112/70 mm Hg. Her calculated BMI is approximately 26 kg/m2. Her heart is without murmurs and lung sounds are clear bilaterally. Standard prenatal testing is ordered. Which of the following is the next best step for this patient’s prenatal care?

• A. MMR vaccine during pregnancy
• B. Serology, then vaccine postpartum
• C. MMR vaccine postpartum (Correct Answer)
• D. Serology, then vaccine during pregnancy
• E. MMR vaccine and immune globulin postpartum

Prenatal Care Explanation: ***MMR vaccine postpartum*** - The **MMR vaccine is a live attenuated vaccine** and therefore **contraindicated during pregnancy** due to the theoretical risk of fetal infection and congenital rubella syndrome. - Vaccinating postpartum ensures the mother develops immunity without any risk to the current pregnancy, and it's also safe for breastfeeding. *MMR vaccine during pregnancy* - Administering a **live attenuated vaccine** like MMR during pregnancy is generally avoided due to the **theoretical risk of teratogenicity**. - While documented cases of congenital rubella syndrome from the vaccine are rare, the risk is not zero, making it unsafe for routine administration during gestation. *Serology, then vaccine postpartum* - The patient's records already indicate she is **MMR non-immune**, rendering additional serology unnecessary to determine her immune status. - The crucial step is the timing of vaccination, which should be postpartum, regardless of repeat serology findings. *Serology, then vaccine during pregnancy* - As explained, **MMR vaccination is contraindicated during pregnancy**, making immediate vaccination during gestation an inappropriate course of action. - While serology can confirm non-immunity, it doesn't change the recommendation to delay vaccination until after delivery. *MMR vaccine and immune globulin postpartum* - **Immune globulin** is typically given for passive immunity following exposure to certain diseases if the patient is non-immune (e.g., RhoGAM for Rh-negative mothers). - It is **not routinely administered with the MMR vaccine postpartum** for healthy, non-immune individuals, as the vaccine itself stimulates active immunity.

Prenatal Care US Medical PG Question 4: A 29-year-old G1P0 female at 32 weeks gestation presents to the emergency department with vaginal bleeding. She has had minimal prenatal care to-date with only an initial visit with an obstetrician after a positive home pregnancy test. She describes minimal spotting that she noticed earlier today that has progressed to larger amounts of blood; she estimates 30 mL of blood loss. She denies any cramping, pain, or contractions, and she reports feeling continued movements of the baby. Ultrasound and fetal heart rate monitoring confirm the presence of a healthy fetus without any evidence of current or impending complications. The consulted obstetrician orders blood testing for Rh-status of both the mother as well as the father, who brought the patient to the hospital. Which of the following represents the best management strategy for this situation?

• A. After 28 weeks gestation, administration of RhoGAM will have no benefit
• B. If mother is Rh-positive and father is Rh-negative then administer RhoGAM
• C. If mother is Rh-negative and father is Rh-negative then administer RhoGAM
• D. If mother is Rh-negative and father is Rh-positive, RhoGAM administration is not needed
• E. If mother is Rh-negative and father is Rh-positive then administer RhoGAM (Correct Answer)

Prenatal Care Explanation: ***If mother is Rh-negative and father is Rh-positive then administer RhoGAM*** - This combination creates a risk for **Rh incompatibility**, meaning the fetus could be Rh-positive and the mother's immune system could form antibodies against fetal red blood cells, which can harm the fetus in future pregnancies. - **RhoGAM (Rh immunoglobulin)** administration prevents the mother from forming these antibodies when there's a risk of maternal-fetal blood mixing, as indicated by vaginal bleeding. *After 28 weeks gestation, administration of RhoGAM will have no benefit* - This statement is incorrect; **RhoGAM is routinely administered around 28 weeks gestation** as prophylaxis in Rh-negative mothers, even without bleeding episodes, to prevent sensitization. - In cases of potential fetal-maternal hemorrhage, such as vaginal bleeding, RhoGAM is indicated regardless of gestational age beyond the first trimester. *If mother is Rh-positive and father is Rh-negative then administer RhoGAM* - This scenario does not pose a risk for **Rh incompatibility hemolytic disease of the newborn**, as the mother already possesses the Rh antigen. - RhoGAM is specifically given to Rh-negative mothers to prevent their immune system from reacting to an Rh-positive fetus. *If mother is Rh-negative and father is Rh-negative then administer RhoGAM* - In this case, both parents are **Rh-negative**, meaning the fetus will also be Rh-negative. - There is no risk of **Rh incompatibility** or sensitization, so RhoGAM administration is not indicated. *If mother is Rh-negative and father is Rh-positive, RhoGAM administration is not needed* - This statement is incorrect and represents a critical misunderstanding of **Rh incompatibility prophylaxis**. - This specific genetic combination creates the highest risk for **Rh sensitization** during pregnancy, especially with events like vaginal bleeding, making RhoGAM administration essential.

Prenatal Care US Medical PG Question 5: A 35-year-old woman gravida 2, para 1, comes to the physician for her first prenatal visit. Pregnancy and delivery of her first child were uncomplicated. She is not sure about the date of her last menstrual period. Pelvic examination shows a uterus consistent in size with a 10-week gestation. An ultrasound examination confirms the gestational age and shows one fetus with no indication of multiple gestations. During counseling on pregnancy risks and possible screening and diagnostic tests, the patient states she would like to undergo screening for Down syndrome. She would prefer immediate and secure screening with a low risk to herself and the fetus. Which of the following is the most appropriate next step in management at this time?

• A. Nuchal translucency, pregnancy-associated plasma protein-A, human chorionic gonadotropin
• B. Maternal serum α-fetoprotein, human chorionic gonadotropin, unconjugated estriol, and inhibin A
• C. Chorionic villus sampling
• D. Amniocentesis
• E. Cell-free fetal DNA testing (Correct Answer)

Prenatal Care Explanation: ***Cell-free fetal DNA testing*** - This is the most appropriate choice given the patient's desire for **immediate and secure screening with low risk** because it is a **non-invasive prenatal screening (NIPS)** method offering high sensitivity and specificity for Down syndrome, particularly in higher-risk pregnancies. - It involves a simple maternal blood draw and can be performed as early as **10 weeks of gestation**, perfectly aligning with the patient's current gestational age and desire for early screening. *Nuchal translucency, pregnancy-associated plasma protein-A, human chorionic gonadotropin* - This combination represents the **first-trimester combined screen**, which is typically performed between 11 and 14 weeks of gestation. While suitable for early screening, **cell-free DNA testing offers higher detection rates and lower false-positive rates** for Down syndrome. - The patient specifically asked for the most **secure and least risky** screening, and NIPS outperforms the combined screen in terms of diagnostic accuracy for aneuploidies. *Maternal serum α-fetoprotein, human chorionic gonadotropin, unconjugated estriol, and inhibin A* - This refers to the **quad screen**, which is typically performed in the **second trimester (15-20 weeks)**, making it too late for the patient's desire for immediate screening at 10 weeks gestational age. - While a widely used screening tool, the quad screen has a **lower detection rate** for Down syndrome compared to cell-free DNA testing. *Chorionic villus sampling* - **Chorionic villus sampling (CVS)** is a **diagnostic, invasive procedure** that carries a small risk of miscarriage (approximately 1 in 455 or 0.22%) and is not a screening test. - Although it can be performed earlier (typically between 10 and 13 weeks), the patient specifically requested a **low-risk screening** option, which CVS is not. *Amniocentesis* - **Amniocentesis** is also an **invasive diagnostic procedure** with a risk of miscarriage (approximately 1 in 900 or 0.11%) and is typically performed in the **second trimester (15-20 weeks)**. - This option is unsuitable because the patient is at 10 weeks gestation and desires **immediate and low-risk screening**, not a diagnostic procedure with procedural risks a few weeks later.

Prenatal Care Flashcard 1 of 5

Question: Should you screen universally for substance abuse in pregnant patients?_____

Answer: Yes

Prenatal Care Flashcard 2 of 5

Question: _____ is the presence of too little amniotic fluid and may be associated with placental insufficiency, bilateral renal agenesis, and posterior urethral valves (inability to excrete urine)

Answer: Oligohydramniosis

Prenatal Care Flashcard 3 of 5

Question: During pregnancy, a woman may experience intermittent sharp pain due to sudden movements of the stretching _____ ligament

Answer: round

Prenatal Care Flashcard 4 of 5

Question: Pregnant women are at risk of _____ transfer of toxoplasmosis

Answer: trans-placental

Prenatal Care Flashcard 5 of 5

Question: In areas with prenatal care, hydatidiform mole is diagnosed by routine _____ early in the first trimester

Answer: ultrasound